Deletion of either ATG3 or LC3 can at least partially block the UBE2C-mediated enhancement in invasive growth, migration, and EMT as well as the reduction in apoptosis and cell cycle arrests in NSCLC (Fig. 4). Here, ATG3 is linked to non-small cell lung carcinoma.